Aydin Pooli¹, Sudhir Isharwal², Gates Cook³, Jennifer M. Oliveto⁴, Chad A. LaGrange¹

Canadian Journal of Urology, Vol.23, No.6, pp. 8564-8567, 2016

Abstract Introduction: We sought to investigate the association of preprostatectomy magnetic resonance imaging (MRI) and surgical pathologic findings in patients with prostate cancer.
Materials and methods: All patients with prostate cancer and preprostatectomy MRI available between 2002 and 2015 were included. Age, prostate-specific antigen at diagnosis, Gleason score at biopsy, MRI technique, radiology report suggestive of prostate cancer, extraprostatic invasion and seminal vesicle involvement, lymphadenopathy and final pathology report were retrospectively reviewed. Data was analyzed for sensitivity, specificity, positive and negative predictive values of MRI findings for predicting T3 disease. Consistency of MRI findings with pathology report was… More >

Haidar M. Abdul-Muhsin, Mark D. Tyson, Karen L. Stern, Rafael A. Nunez-Nateras, Mitchell R. Humphreys

Canadian Journal of Urology, Vol.23, No.6, pp. 8557-8563, 2016

Abstract Introduction: To systemically measure the impact of trainees' participation on the perioperative and functional outcomes after holmium laser enucleation of the prostate (HoLEP).
Materials and methods: Benign prostatic hyperplasia patients who underwent HoLEP at our department between January 2007 and January 2013 were classified based on trainee's level. Perioperative outcomes and complications were collected. Functional outcomes were assessed using the Sexual Health Inventory for Men (SHIM), International Prostate Symptom Score (IPSS), and International Continence Society-Short Form (ICSmaleSF) questionnaires. Voiding and incontinence domains of ICSmaleSF were assessed separately. Patients were divided into group 1 if no trainee participated… More >

Patrick J. Hensley^1,2, Lisa R. Bailey¹, Matthew S. Purdom², Daniel L. Davenport³, Stephen E. Strup¹

Canadian Journal of Urology, Vol.23, No.6, pp. 8551-8556, 2016

Abstract Introduction: This study investigated the polar sub-localization of prostate cancer on needle core biopsy ("polar" defined as tumor ≤ 1 mm from the tissue polar edge) as a predictor of extraprostatic extension.
Materials and methods: Histologic sections from 58 patients who underwent preoperative prostate biopsy and radical prostatectomy at the University of Kentucky from 2006 to 2013 were evaluated. Patients were retrospectively case matched based on pathologic stage (pT2 versus pT3/4) using biopsy Gleason grade and prostate-specific antigen. Histologic sections of needle core biopsies were analyzed for polar involvement. The location of polar involvement was correlated to… More >

M. Ryan Farrell¹, Sheila A. Dugan², Laurence A. Levine¹

Canadian Journal of Urology, Vol.23, No.6, pp. 8546-8550, 2016

Abstract Introduction: Chronic scrotal content pain (CSCP) is a common condition that can be challenging to manage definitively. A cohort of patients with CSCP have referred pain from myofascial abnormalities of the pelvic floor and therefore require treatment modalities that specifically address the pelvic floor such as pelvic floor physical therapy (PFPT).
Materials and methods: Retrospective chart review of all men with a pelvic floor component of CSCP presenting to our tertiary care medical center and undergoing PFPT from 2011-2014. Patients with CSCP and pain/tightness on pelvic floor evaluation with 360° digital rectal exam (DRE) were referred to… More >

Matthew E. Johnson^1,*, Nicholas G. Zaorsky^1,*, Jeffrey M. Martin¹, Karen Ruth², Richard E. Greenberg³, Robert G. Uzzo³, Shelly B. Hayes¹, Marc C. Smaldone³, Alexander Kutikov³, Rosalia Viterbo³, David Y. T. Chen³, Mark A. Hallman¹, Mark L. Sobczak¹, Eric M. Horwitz¹

Canadian Journal of Urology, Vol.23, No.6, pp. 8535-8545, 2016

Abstract Introduction: To characterize patient reported outcomes for urinary and sexual function using International Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) comparing intensity modulated radiation therapy (IMRT), low dose rate brachytherapy (LDR), post-prostatectomy IMRT (PPRT), and radical prostatectomy (RP).
Materials and methods: Patients treated for prostate cancer from 2001-2012 completed self-reported SHIM and IPSS surveys. Subgroups were created by baseline score. Mean change from baseline was determined at each time point for the cohort and subgroups. Statistical analysis was performed with generalized estimating equation method. Incontinence was not captured in the questionnaires.
Results: A total… More >

Ruben F. Gittes

Canadian Journal of Urology, Vol.23, No.6, pp. 8533-8534, 2016

Abstract This article has no abstract. More >

Fernando Calais da Silva

Canadian Journal of Urology, Vol.23, No.6, pp. 8531-8532, 2016

Abstract This article has no abstract. More >

Francis X. Keeley Jr.

Canadian Journal of Urology, Vol.23, No.6, pp. 8530-8530, 2016

Abstract This article has no abstract. More >

Manal El-Hamamsy^*, Hesham Elwakil^†, Amr S. Saad^†, May A. Shawki^*

Oncology Research, Vol.24, No.6, pp. 521-528, 2016, DOI:10.3727/096504016X14719078133528

Abstract Statins have been reported to have a potential radiosensitizing effect that has not been evaluated in clinical trials. The aim of this study was to evaluate the efficacy and safety of simvastatin in addition to whole-brain radiation therapy (WBRT) in patients with brain metastases (BM). A prospective randomized, controlled, open-label pilot study was conducted on 50 Egyptian patients with BM who were randomly assigned to receive 30-Gy WBRT (control group: 25 patients) or 30 Gy WBRT+ simvastatin 80 mg/day for the WBRT period (simvastatin group: 25 patients). The primary outcome was radiological response at 4… More >

Yanhua Li^*1, Xia Chen^†1, Hong Lu^*

Oncology Research, Vol.24, No.6, pp. 511-519, 2016, DOI:10.3727/096504016X14719078133483

Abstract The gene solute carrier family 34 (sodium phosphate), member 2 (SLC34A2), is a member of the SLC34 family. Increasing evidence suggests that SLC34A2 is involved in the development of many human carcinomas. However, its role in hepatocellular carcinoma (HCC) is still unclear. Therefore, in this study we investigated the role of SLC34A2 in HCC and explored the underlying mechanism. We found that the expression of SLC34A2 is upregulated in HCC cell lines. Knockdown of SLC34A2 obviously inhibited HCC cell proliferation, migration/invasion, and the epithelial–mesenchymal transition (EMT) phenotype. Furthermore, knockdown of SLC34A2 significantly inhibited the expression More >